Related references
Note: Only part of the references are listed.STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
L. L. Bu et al.
JOURNAL OF DENTAL RESEARCH (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
The good and the bad faces of STAT1 in solid tumours
Katrin Meissl et al.
CYTOKINE (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
The promise of immunotherapy in head and neck squamous cell carcinoma
P. Economopoulou et al.
ANNALS OF ONCOLOGY (2016)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J. M. Kim et al.
ANNALS OF ONCOLOGY (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
K. M. Morrissey et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes et al.
TRENDS IN IMMUNOLOGY (2016)
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Sjoerd H. van der Burg et al.
NATURE REVIEWS CANCER (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
J. Hun Hah et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Siwen Hu-Lieskovan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine
Lorenzo Mortara et al.
CANCER MEDICINE (2013)
Strategies to counteract MHC-I defects in tumors
Margit H. Lampen et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
PD-L1 expression on tolerogenic APCs is controlled by STAT-3
Sabine J. Woelfle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Greta Garrido et al.
JOURNAL OF IMMUNOLOGY (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)
Immune Suppression in Head and Neck Cancers: A Review
Anaelle Duray et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Dysregulated molecular networks in head and neck carcinogenesis
Alfredo A. Molinolo et al.
ORAL ONCOLOGY (2009)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Share Paper
